

Healthy Volunteers

A study to look at how safe different doses of a new study medicine (RO7303509) were for healthy people to take – and how this medicine was processed through the body

| | | |
|----------------------------------|-------------------------------------|------------------------------------|
| Trial Status Completed | Trial Runs In 1 Countries | Trial Identifier GA42285 |
|----------------------------------|-------------------------------------|------------------------------------|

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This clinical trial investigated a new medicine called, “RO7303509”, for the treatment of “systemic sclerosis”. This study was done to find out how safe it was for healthy people to get a single treatment of this study medicine. Different groups of people were given different doses of RO7303509. This was a phase 1a, randomized, double#blind, placebo-controlled, single ascending-dose study in healthy volunteers.

| | |
|--|--------------------------|
| Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland) Sponsor | Phase 1a Phase |
|--|--------------------------|

GA42285
Trial Identifiers

Eligibility Criteria:

| | | |
|-----------------------|------------------------------|----------------------------------|
| Gender Both | Age 18 to 75 years | Healthy Volunteers Yes |
|-----------------------|------------------------------|----------------------------------|

Healthy volunteers were enrolled at one study site in USA to evaluate the safety and tolerability of RO7303509, a treatment for systemic sclerosis. Forty-nine participants contributed to the final analyses of the safety data in this phase 1a, randomized, double#blind, placebo-controlled, single ascending-dose study. Results showed RO7303509 to be well tolerated; there were some low-grade common side effects, but no deaths, no serious side effects, or side effects leading to study discontinuations.